Clinical Trials in Dallas

Showing 12221-12240 of 17,468 trials

Phase 1 Study of ONT-10 in Patients With Solid Tumors

NCT01556789

Open label, two part, Phase 1 dose escalation study to evaluate the safety and immunogenicity of repeat dose vaccination with ONT-10 in patients with previously treated Stage 3 or 4 solid tumors. Part 1 to evaluate escalating dose levels of ONT-10 administered subcutaneously every two weeks (Q2W) or weekly (QW) over 8 weeks. Part 2 evaluates the safety, immunogenicity, and potential anti-tumor activity of ONT-10 administered over 8 weeks at the Q2W and QW maximum tolerated does/recommended dose (MTD/RD) in cohorts of 15 patients each.

Solid Tumors

Cascadian Therapeutics Inc.85 participantsStarted Mar 2013

Aurora, Colorado, United States • Dallas, Texas, United States • Tacoma, Washington, United States

COMPLETEDPhase 2< 1 mile

PF-00489791 For The Treatment Of Raynaud's

NCT01090492

The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.

Raynaud's DiseasePeripheral Vascular Disease

Pfizer243 participantsStarted Aug 2010

Redwood City, California, United States • Farmington, Connecticut, United States • Washington D.C., District of Columbia, United States +52 more locations

Phase 1 Study of ONT-10 in Patients With Solid Tumors

PF-00489791 For The Treatment Of Raynaud's

Find Trials by Condition in Dallas

Phase 1 and 2 Study of PX-866 and Cetuximab

Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

A Study in Participants With Rheumatoid Arthritis

A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy

Usability of an AI for M923 in Subjects With Moderate to Severe RA

Phase I Trial of Oral PX-866

Cerebral Protection in Transcatheter Aortic Valve Replacement

Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773

Substance Abuse Treatment to HIV Care (SAT2HIV): The Motivational Interviewing-based Brief Intervention Experiment

Radiosurgery or Open Surgery for Epilepsy Trial

A Prospective, Multicenter All Comers Study of Phasix Mesh for Ventral or Incisional Hernia Repair

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma

Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017

The Impact of Vitamin D on Disease Activity in Crohn's Disease